menu
    • menu

    Company profile for CytoDyn

    NEW Drugs in Dev: 1
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    CytoDyn is committed to enhancing the lives of patients through target specific medicine. Our team is focused on developing Leronlimab, a monoclonal antibody CCR5 receptor antagonist, to be used as a platform drug for a variety of indications.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    CytoDynUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1111 Main Street Suite 660 Vancouver, WA 98660
    Telephone
    Telephone
    360-980-8524
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.cytodyn.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/cytodyn-inc
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/cytodyn

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    BePharma

    Not Confirmed

    envelop Contact Supplier

    BePharma

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Cytodyn Secures $17.5M Financing For Leronlimab Development
    Cytodyn Secures $17.5M Financing For Leronlimab Development

    05 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/05/3250164/19782/en/CytoDyn-Closes-17-5-Million-Financing-to-Fund-Continued-Development-of-Leronlimab.html

    GLOBENEWSWIRE
    05 Mar 2026
    Share Share
    CytoDyn Employs Creatv Bio's LifeTracDx in Phase 2 Study
    CytoDyn Employs Creatv Bio's LifeTracDx in Phase 2 Study

    03 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/creatv-bios-lifetracdx-blood-test-utilized-as-exploratory-biomarker-in-cytodyns-phase-2-study-in-patients-with-relapsedrefractory-metastatic-colorectal-cancer-302702502.html

    PR NEWSWIRE
    03 Mar 2026
    Share Share
    CytoDyn Launches Funding For Triple-Negative Breast Cancer
    CytoDyn Launches Funding For Triple-Negative Breast Cancer

    27 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/27/3226507/19782/en/CytoDyn-Announces-Funding-and-Initiation-of-Expanded-Access-Program-for-Patients-with-Triple-negative-Breast-Cancer.html

    GLOBENEWSWIRE
    27 Jan 2026
    Share Share
    Ex-Cytodyn CEO Sentenced As Alleged Co-Conspirator Wins New Trial
    Ex-Cytodyn CEO Sentenced As Alleged Co-Conspirator Wins New Trial

    26 Jan 2026

    // PRESS RELEASE

    https://www.justice.gov/opa/pr/biotech-ceo-sentenced-securities-fraud-scheme

    PRESS RELEASE
    26 Jan 2026
    Share Share
    December 2025 Letter to Shareholders
    December 2025 Letter to Shareholders

    16 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/16/3206218/19782/en/December-2025-Letter-to-Shareholders.html

    GLOBENEWSWIRE
    16 Dec 2025
    Share Share
    CytoDyn Showcases PD-L1 Upregulation, Survival in mTNBC at SABCS
    CytoDyn Showcases PD-L1 Upregulation, Survival in mTNBC at SABCS

    08 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/08/3201537/19782/en/CytoDyn-to-Showcase-PD-L1-Upregulation-and-Improved-Survival-in-Metastatic-Triple-Negative-Breast-Cancer-at-the-San-Antonio-Breast-Cancer-Symposium.html

    GLOBENEWSWIRE
    08 Dec 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search